Cargando…

Metastatic Prostate Cancer to the Optic Canal: A Large-Cohort Analysis

Prostate cancer (PCa) can present with metastases in rare cases, including those to the optic canal. Currently, no guidelines exist for managing PCa metastases in this patient population. This article aims to examine optic canal metastases through a large-cohort analysis. It involves a systematic re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelkar, Neil, Findakly, Dawood, Wang, Jue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625801/
https://www.ncbi.nlm.nih.gov/pubmed/37933347
http://dx.doi.org/10.7759/cureus.46598
_version_ 1785131209473392640
author Kelkar, Neil
Findakly, Dawood
Wang, Jue
author_facet Kelkar, Neil
Findakly, Dawood
Wang, Jue
author_sort Kelkar, Neil
collection PubMed
description Prostate cancer (PCa) can present with metastases in rare cases, including those to the optic canal. Currently, no guidelines exist for managing PCa metastases in this patient population. This article aims to examine optic canal metastases through a large-cohort analysis. It involves a systematic review of the literature through a pooled analysis of published cases of PCa with optic canal or orbital metastasis, including one case previously reported from our institution. A subgroup analysis was employed to compare cases with optic metastases as their initial PCa presentation, hormone-naive (HN), versus those with optic metastases after PCa diagnosis, hormone-refractory (HR).  A total of 45 patients with ocular metastasis from PCa were included in this study. The mean age at diagnosis overall was 66.8 years (range: 45-85 years). Moreover, 16 cases (50%) had deceased, with a median time-to-death of 22 (range: 2-84) months. Regarding subgroup analysis, the mean age at diagnosis was 69.5 years (53-85 years) in the HN group and 64.5 years (45-83 years) in the HR group. With regard to reported survival, 10 (62.5%) cases belonged to the HN subset with a median follow-up duration of 12 (range: 1.5-36) months. In terms of reported mortality, 10 (62.5%) were from the HR subset with a median time-to-death of 32.5 (range 0.5-84) months. Our study constitutes the largest and most comprehensive examination of patients with optic canal metastases due to PCa so far. While optic canal metastases are a rare manifestation of PCa, they are linked with a poor prognosis. We also observed significant differences between HR and HN cohorts, which may indicate a difference in clinical presentations.
format Online
Article
Text
id pubmed-10625801
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-106258012023-11-06 Metastatic Prostate Cancer to the Optic Canal: A Large-Cohort Analysis Kelkar, Neil Findakly, Dawood Wang, Jue Cureus Ophthalmology Prostate cancer (PCa) can present with metastases in rare cases, including those to the optic canal. Currently, no guidelines exist for managing PCa metastases in this patient population. This article aims to examine optic canal metastases through a large-cohort analysis. It involves a systematic review of the literature through a pooled analysis of published cases of PCa with optic canal or orbital metastasis, including one case previously reported from our institution. A subgroup analysis was employed to compare cases with optic metastases as their initial PCa presentation, hormone-naive (HN), versus those with optic metastases after PCa diagnosis, hormone-refractory (HR).  A total of 45 patients with ocular metastasis from PCa were included in this study. The mean age at diagnosis overall was 66.8 years (range: 45-85 years). Moreover, 16 cases (50%) had deceased, with a median time-to-death of 22 (range: 2-84) months. Regarding subgroup analysis, the mean age at diagnosis was 69.5 years (53-85 years) in the HN group and 64.5 years (45-83 years) in the HR group. With regard to reported survival, 10 (62.5%) cases belonged to the HN subset with a median follow-up duration of 12 (range: 1.5-36) months. In terms of reported mortality, 10 (62.5%) were from the HR subset with a median time-to-death of 32.5 (range 0.5-84) months. Our study constitutes the largest and most comprehensive examination of patients with optic canal metastases due to PCa so far. While optic canal metastases are a rare manifestation of PCa, they are linked with a poor prognosis. We also observed significant differences between HR and HN cohorts, which may indicate a difference in clinical presentations. Cureus 2023-10-06 /pmc/articles/PMC10625801/ /pubmed/37933347 http://dx.doi.org/10.7759/cureus.46598 Text en Copyright © 2023, Kelkar et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Ophthalmology
Kelkar, Neil
Findakly, Dawood
Wang, Jue
Metastatic Prostate Cancer to the Optic Canal: A Large-Cohort Analysis
title Metastatic Prostate Cancer to the Optic Canal: A Large-Cohort Analysis
title_full Metastatic Prostate Cancer to the Optic Canal: A Large-Cohort Analysis
title_fullStr Metastatic Prostate Cancer to the Optic Canal: A Large-Cohort Analysis
title_full_unstemmed Metastatic Prostate Cancer to the Optic Canal: A Large-Cohort Analysis
title_short Metastatic Prostate Cancer to the Optic Canal: A Large-Cohort Analysis
title_sort metastatic prostate cancer to the optic canal: a large-cohort analysis
topic Ophthalmology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625801/
https://www.ncbi.nlm.nih.gov/pubmed/37933347
http://dx.doi.org/10.7759/cureus.46598
work_keys_str_mv AT kelkarneil metastaticprostatecancertotheopticcanalalargecohortanalysis
AT findaklydawood metastaticprostatecancertotheopticcanalalargecohortanalysis
AT wangjue metastaticprostatecancertotheopticcanalalargecohortanalysis